Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.
Ingo K MellinghoffMarta Penas-PradoKatherine B PetersHoward A BurrisElizabeth A MaherFilip JankuGregory M CoteMacarena I de la FuenteJennifer L ClarkeBenjamin M EllingsonSaewon ChunRobert J YoungHua LiuSung ChoeMin LuKha LeIslam HassanLori SteelmanShuchi S PandyaTimothy F CloughesyPatrick Y WenPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Vorasidenib was well tolerated and showed preliminary antitumor activity in patients with recurrent or progressive nonenhancing mIDH LGG.